Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts

Kindred Biosciences (NASDAQ:KIN) has been assigned a $10.00 price target by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 33.33% from the stock’s current price.

Several other research analysts have also recently weighed in on KIN. B. Riley set a $11.00 price target on Kindred Biosciences and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research cut Kindred Biosciences from a “buy” rating to a “hold” rating and set a $8.50 price target for the company. in a research report on Tuesday, September 12th. Finally, ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $9.63.

Kindred Biosciences (NASDAQ KIN) traded down $0.10 during trading on Tuesday, hitting $7.50. The company had a trading volume of 85,800 shares, compared to its average volume of 144,079. Kindred Biosciences has a 12-month low of $3.90 and a 12-month high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. analysts expect that Kindred Biosciences will post -1.18 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in shares of Kindred Biosciences by 2.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,369,688 shares of the biopharmaceutical company’s stock valued at $9,656,000 after buying an additional 34,735 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Kindred Biosciences by 57.7% in the second quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after buying an additional 272,612 shares in the last quarter. General American Investors Co. Inc. purchased a new stake in shares of Kindred Biosciences in the third quarter valued at approximately $5,232,000. Renaissance Technologies LLC increased its position in shares of Kindred Biosciences by 43.6% in the first quarter. Renaissance Technologies LLC now owns 504,800 shares of the biopharmaceutical company’s stock valued at $3,559,000 after buying an additional 153,200 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Kindred Biosciences by 2.2% in the third quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock worth $2,650,000 after acquiring an additional 7,206 shares during the last quarter. Institutional investors and hedge funds own 66.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/05/kindred-biosciences-kin-given-a-10-00-price-target-by-hc-wainwright-analysts.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply